The number of deals is down from last year, but most firms have still been fairly active in the private markets.
Stephen TaubDecember 21, 2022
Carsten Snejbjerg/Bloomberg
Biopharma-focused hedge funds have cut back sharply on their private venture capital investments in 2022, but not to the extent of the tech-focused firms. Yes, they all participated in fewer private fundraisings
To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.